Shown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by europerep on June 27, 2010, at 14:23:31
hey there...
I just found a very short article on the implication of endocannabinoids, or rather a lack thereof, in depression, and how this might be a new pathway leading to novel antidepressant treatment.
this is apparently still in very early stages, but it's by scientists from, among others, McGill and Vanderbilt..http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(09)00121-7
finally the confirmation of what I have always been suspecting or what I have experienced actually.. it's sad it will take the regular time of developing a drug + the "bad receptor" delay.. seeing how long it took for thc in pain management it may actually be quite long, but maybe we are a step further today.. I sure hope so..
Posted by linkadge on June 27, 2010, at 19:20:25
In reply to endocannabinoid system in novel antidepressants, posted by europerep on June 27, 2010, at 14:23:31
Interesting. The TCA antidepresssants increase the activity of the endocannabanoid system. The antidepressant citalopram actually decreases it.
Linkadge
Posted by TenMan on June 28, 2010, at 15:33:09
In reply to Re: endocannabinoid system in novel antidepressants, posted by linkadge on June 27, 2010, at 19:20:25
Hyperforin, one of the active constituents in St. John's Wort, potently activates TRPC6 channels which when activated increase levels of endogenous endocannabinoids.
Posted by desolationrower on June 30, 2010, at 16:31:49
In reply to Re: endocannabinoid system in novel antidepressants, posted by TenMan on June 28, 2010, at 15:33:09
Rimonabant was a anti-obesity drug that also reduced smoking and other addictive behavior.
It causes depression though.
It is a CB1 inverse agonist.
-d/r
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.